Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 in adolescent patients with Fragile X syndrome
2010-022638-96Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Fragile X syndrome (FXS) comparing AFQ056 100 mg BID with Placebo (2 arms). Primary endpoint: Primary: Change in ABC-CFX total score. Started Feb 2011; status: completed.
02
Drugs
mavoglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on 2010-022638-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022638-96.